about
Atypical hemolytic uremic syndromeRecessive mutations in DGKE cause atypical hemolytic-uremic syndromeEculizumab safely reverses neurologic impairment and eliminates need for dialysis in severe atypical hemolytic uremic syndromeClinical features of anti-factor H autoantibody-associated hemolytic uremic syndromeRelative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotypeDifferent disparities of gender and race among the thrombotic thrombocytopenic purpura and hemolytic-uremic syndromesThrombotic microangiopathy with targeted cancer agentsClinical Practice Guidelines for the Management of Atypical Hemolytic Uremic Syndrome in KoreaOverview of C3 GlomerulopathyAdvances and challenges in the management of complement-mediated thrombotic microangiopathiesHemolytic uremic syndromeComplement cascade and kidney transplantation: The rediscovery of an ancient enemyTherapeutic regulation of complement in patients with renal disease - where is the promise?Atypical haemolytic uraemic syndrome with underlying glomerulopathies. A case series and a review of the literatureA new paradigm: Diagnosis and management of HSCT-associated thrombotic microangiopathy as multi-system endothelial injuryManagement of hemolytic-uremic syndrome in childrenCurrent treatment of atypical hemolytic uremic syndromeAtypical hemolytic-uremic syndrome: a case report and literature reviewStructural Basis for Eculizumab-Mediated Inhibition of the Complement Terminal PathwayClinical evaluation of thrombotic microangiopathy: identification of patients with suspected atypical hemolytic uremic syndromeHematopoietic cell transplantation-associated thrombotic microangiopathy: a review of pathophysiology, diagnosis, and treatmentComplement System Part II: Role in ImmunityEculizumab: a review of its use in atypical haemolytic uraemic syndromeThree-dimensional reconstruction of protein networks provides insight into human genetic diseaseA systematic review of eculizumab for atypical haemolytic uraemic syndrome (aHUS)Mutations in complement regulatory proteins predispose to preeclampsia: a genetic analysis of the PROMISSE cohortComplement: a key system for immune surveillance and homeostasisEscherichia coli diseases in Latin America-a 'One Health' multidisciplinary approach.Haemolytic uraemic syndrome.Guidelines on the Use of Therapeutic Apheresis in Clinical Practice-Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Seventh Special Issue.Renal complications of seasonal and pandemic influenza A virus infections.Pros and cons for C4d as a biomarker.Epidemiology of haemolytic uremic syndrome in children. Data from the North Italian HUS network.Pregnancy-associated hemolytic uremic syndrome revisited in the era of complement gene mutations.Myocardial infarction is a complication of factor H-associated atypical HUS.Atypical hemolytic uremic syndrome in the Tunisian population.Triggering of atypical hemolytic uremic syndrome by influenza A (H1N1).aHUS caused by complement dysregulation: new therapies on the horizon.The role of endothelial cell injury in thrombotic microangiopathy.Advances in our understanding of the pathogenesis of glomerular thrombotic microangiopathy.
P2860
Q21202864-858AC588-6AF6-43ED-B7AB-D97209AE2505Q24337607-640426DA-6BF0-44F7-9FA1-88AE2FE282AFQ24605432-42959448-E266-4D82-AE06-012580137CACQ24606843-B80D6DEE-D47E-49FF-829F-F3B5F8B0972CQ24613907-745FEA0B-1E2B-49F9-B2EF-CDEDB4CA06D4Q24616851-7C061ACE-2FBE-4602-9169-0CF5515F587AQ24635904-130FAD8E-C764-422A-8DE9-C5A6CA501C30Q26739894-C6FED891-E843-43AD-9701-DF6D17061C79Q26747262-8DE7C09F-E24C-4CB7-8279-A92E2C8AC5F0Q26796453-5FE51F72-C0EA-4AD7-BB36-3FC43F5D1C74Q26799054-D81305AE-F0B8-48D2-9466-DE9E8120C178Q26829790-9B2435B8-CC89-41AC-A31A-92151903FE9EQ26851705-F39ADF9F-1C93-4F90-BFF0-279337986042Q26864297-0F18D002-9E72-47BF-91F7-ED16A0458553Q26992169-13D435D0-2F48-4DDA-B2FB-53635BB6F00CQ27002576-B8285997-B7A6-4427-AC41-52EB6AC62150Q27003211-CFF5B2DD-CDDE-4F7D-817F-23A51970085DQ27003863-6FD7578E-B540-4433-A055-3FDC4ED85F56Q27704898-963151A0-33F3-4D00-AC72-FCD2E3E710B4Q28067041-CBA14DA7-886B-42DC-A246-41F415D80E63Q28069228-7D6D4F19-DB32-4618-ACCF-A95CBBFEE091Q28263460-375F4A01-F5A9-4D57-8320-A47AC45A37F4Q28302228-7BEC71A0-3306-4BD0-956B-8EF73928F832Q28530021-2E147C1A-877D-4008-8BF3-88A831D94C52Q28661698-AABB0E41-581D-4EA7-AE3E-77C9B161D00FQ28741729-01061E9B-BE10-402E-B321-AE2CB985A942Q29615484-CD5878FC-D0FB-4308-AEA2-DC4561C95ADAQ30238608-BD28B9BE-F8ED-4BE2-92A2-E0E4CEEC1DD4Q30244707-4B469535-CB0F-4D10-AD95-9EE45EA27564Q30276550-730899A3-7AA2-4B06-A40A-59C448CF798DQ30422342-1A42FB58-527A-41D7-809D-3EA057509C64Q30544649-BCE86526-1F8E-4395-9541-32BFB91B38D2Q31010561-CEB19197-A4EB-44C0-890B-6D954863FDEBQ33388474-7D13AD4F-D327-4D68-A377-1169DA3D6383Q33388820-914CA689-BD00-4A81-8EED-E019F778F71BQ33389773-19CB2329-72AB-4C9B-B8DC-E1E4A533DC6CQ33390080-3A7F1521-B477-4D49-A477-C5052A02FD41Q33390198-D1AAA8E9-98D0-4847-B0C9-7CFC3C7C26DDQ33391882-D8E3C085-8875-4160-804F-6B4C3FA2772CQ33392316-2AD6AB50-0761-4DD6-BCC5-D95EDF82FCAD
P2860
description
2009 nî lūn-bûn
@nan
2009 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Atypical hemolytic-uremic syndrome.
@ast
Atypical hemolytic-uremic syndrome.
@en
type
label
Atypical hemolytic-uremic syndrome.
@ast
Atypical hemolytic-uremic syndrome.
@en
prefLabel
Atypical hemolytic-uremic syndrome.
@ast
Atypical hemolytic-uremic syndrome.
@en
P356
P1476
Atypical hemolytic-uremic syndrome.
@en
P2093
Marina Noris
P304
P356
10.1056/NEJMRA0902814
P407
P577
2009-10-01T00:00:00Z